An analysis of phase 3 trials found tamoxifen significantly reduced 15-year ipsilateral breast recurrence in patients with ...

Researchers examined pooled data from two clinical trials that enrolled patients with low- or intermediate-grade ductal ...

This conclusion comes from the phase 3 study EA4151, conducted by the ECOG-ACRIN Cancer Research Group. The trial, which ...

For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the ...

For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive ...

In NRG/RTOG 9804, patients with "good-risk" DCIS were randomly assigned to receive radiotherapy or no radiotherapy. In ECOG-ACRIN E5194, researchers examined the outcomes of patients with both ...

A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following ...

Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma compared with Rituxan alone.

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ...